China News Service, January 18th (Zuo Yuqing, Zhongxin Finance and Economics) The annual "soul bargaining" between experts from the Medical Insurance Bureau and representatives of pharmaceutical companies came to an end. For the first time, oral drugs for new crowns, high-value tumor drugs, and new drugs for rare diseases began to "talk" ", became the focus of this medical insurance negotiation.
So, what was the outcome of the negotiations?
On the 18th, the National Medical Insurance Administration held a press conference to introduce the relevant situation of the adjustment of the National Medical Insurance Drug Catalog in 2022.
On the 18th, the National Medical Insurance Administration held a press conference to introduce the relevant situation of the adjustment of the National Medical Insurance Drug Catalog in 2022.
Photo by Zuo Yuqing
How much can patients save?
——It is estimated that the burden on patients will be reduced by more than 90 billion yuan in the next two years
According to Huang Xinyu, deputy director of the Medical Service Management Department of the National Medical Insurance Administration, the adjustment of the national basic medical insurance, work-related injury insurance and maternity insurance drug catalogs in 2022 has been successfully completed.
In this adjustment, a total of 111 drugs were added to the catalog.
The newly added drugs include 56 drugs for chronic diseases such as hypertension, diabetes, hyperlipidemia, and psychosis, 23 drugs for tumors, 17 drugs for anti-infection, 7 drugs for rare diseases, 2 drugs for the treatment of new coronary pneumonia, and other fields. There are 6 kinds of medicines.
After this round of adjustments, the total number of drugs in the national medical insurance drug catalog has reached 2,967, including 1,586 Western medicines and 1,381 Chinese patent medicines; Chinese herbal medicines have not been adjusted, and the number is still 892.
Judging from the negotiation and bidding situation, 147 drugs outside the list participated in the negotiation and bidding (including the renewal negotiation of drugs in the original list), and 121 drugs were successfully negotiated or bid, with an overall success rate of 82.3%.
Negotiations and bidding for newly admitted drugs saw an average price drop of 60.1%, basically the same as last year.
From the perspective of patient burden, through the dual burden reduction effect of price reduction through negotiation and medical insurance reimbursement, this adjustment is expected to reduce the burden on patients by more than 90 billion yuan in the next two years.
Huang Xinyu said that in the past five years, the National Medical Insurance Bureau has adhered to the functional orientation of "guaranteeing the basics", resolutely put an end to sky-high prices for drugs to enter the medical insurance, and relied on China's huge market size to substantially reduce the prices of drugs that were newly included in the list through negotiation.
In many therapeutic fields, the price of medicines in China has changed from a highland to a lowland in the world. For the first time, Chinese medicine prices have become a reference for drug pricing in developed countries.
"From 2018 to 2022, imported drugs basically offered the lowest prices in the world. In 2022, an innovative method of bidding access was proposed, which solved the problem that some non-exclusive drugs had high prices and were difficult to enter the catalog, and guided enterprises to use the price of bidding. The form actively lowers the price in exchange for the opportunity to enter the medical insurance catalog." He said.
Data map: Azivudine tablets.
Photo by Yin Liqin
What is the result of the negotiations on the treatment of the new crown?
——Azvudine Tablets and other two drugs were officially included in the National Medical Insurance List
Previously, the person in charge of the National Medical Insurance Bureau revealed that this year, a total of three new crown treatment drugs, Azvudine Tablets, Naimatevir Tablets/Ritonavir Tablets Combination Packaging ("Paxlovid"), and Qingfei Paidu Granules, passed the self-declaration of enterprises. , form review, expert review and other procedures, participated in the negotiation.
So how did the negotiations turn out?
According to Huang Xinyu, this medical insurance negotiation fully supports the treatment of new coronavirus infection.
For the third consecutive year, new crown treatment drugs have been included as a condition for admission to the national medical insurance catalog. Two drugs, including Azivudine Tablets and Qingfei Paidu Granules, will be officially included in the national medical insurance catalog after price reductions through negotiations.
Among the 25 marketed drugs involved in the tenth edition of the new coronavirus infection diagnosis and treatment plan, 21 varieties have been officially included in the national medical insurance catalog.
As for Paxlovid, which failed to be included in the medical insurance catalog through negotiation due to Pfizer’s high quotation, relevant sources revealed that they will no longer hold special negotiations with Pfizer on Paxlovid.
In addition, Merck's monogravir capsules will not be additionally negotiated.
"Under normal circumstances, the negotiation of the medical insurance catalog is only held once a year."
Data map: In a community health service center in Beijing, medical staff are putting the delivered medicines into the medicine racks.
Photo by China News Agency reporter Yi Haifei
In which key areas should drugs be used to make up for shortcomings?
——Support domestic major innovative drugs to enter the catalog
Huang Xinyu said that medical insurance negotiations continue to support the entry of drugs in key areas, including domestic innovative drugs, new crown therapeutic drugs, children's medicines and other key areas of disease, major diseases such as rare tumor diseases, and chronic diseases such as diabetes and COPD.
"These drugs have been further included in the catalogue, making up for the shortcomings of the catalogue, and improving the level of protection."
It is reported that a total of 24 major domestic innovative drugs were included in the negotiation this time, and finally 20 drugs such as Orebatinib were successfully negotiated, with a success rate of 83.3%, which was higher than the overall negotiation success rate.
At the same time, 7 drugs for rare diseases, 22 drugs for children, and 2 essential drugs were successfully included in the list.
"Most of the newly added drugs in this catalog are newly marketed drugs within five years." Huang Xinyu pointed out that 23 drugs were included in the catalog in the year they were launched in 2022.
For example, in the field of lung cancer, this negotiation not only added new drugs with significant efficacy such as lorlatinib and ceritinib, but also significantly reduced the prices of drugs such as ensartinib and ceritinib in the original list.
"Doctors and patients have more clinical options." Huang Xinyu said.
(Finish)
search
copy